TALL 104

Drug Profile

TALL 104

Alternative Names: ABIO-05/01; ABIO-0501; TALL-104

Latest Information Update: 01 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wistar Institute
  • Developer Abiogen Pharma; Galileo Research; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cell therapies; Immunotherapies
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ovarian cancer
  • No development reported Peritoneal cancer
  • Discontinued Chronic myeloid leukaemia

Most Recent Events

  • 29 Jul 2015 No recent reports on development identified - Phase-I/II for Peritoneal cancer in Italy (IV & Intraperitoneal)
  • 13 Feb 2014 No development reported - Phase-II for Ovarian cancer in Italy (Parenteral)
  • 01 May 2013 Abiogen Pharma terminates phase I trial in Chronic myeloid leukaemia (combination therapy, second-line therapy or greater) in USA (NCT00415909)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top